B
Brooke Mallory
Guest
A ground-breaking gene-editing therapy for sickle cell disease, a debilitating ailment that affects around 100,000 Americans, the majority of whom are people of color (POC), was authorized by the U.S. Food and Drug Administration (FDA) on Friday.
Continue reading...
Continue reading...